Why the study?
The study sought to compare the effects of intracoronary tenecteplase versus abciximab in patients with STEMI undergoing PPCI.
Does intracoronary reduced-dose tenecteplase reduce infarct size compared to abciximab in patients with anterior STEMI undergoing PPCI?
Does intracoronary reduced-dose tenecteplase reduce infarct size compared to abciximab in patients with anterior STEMI undergoing PPCI?
Intracoronary tenecteplase during PPCI for anterior STEMI did not reduce infarct size compared to abciximab and was associated with poorer myocardial reperfusion and potentially increased subacute stent thrombosis.
Answers are grounded in this paper and cite their sources.
Intracoronary tenecteplase offers no infarct size advantage over abciximab in anterior STEMI; challenges its adjunctive use during PPCI.
AIMS: We sought to compare the effects of intracoronary administration of a fibrinolytic drug (tenecteplase) to those of a glycoprotein IIb/IIIa inhibitor (abciximab) in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). METHODS AND RESULTS: In this pilot trial, 76 patients (59 male) with anterior STEMI were randomised to intracoronary infusion of reduced-dose tenecteplase or abciximab during PPCI. Angiography was repeated at 48 hours to assess corrected TIMI frame count (cTFC) and TIMI myocardial perfusion grade (TMPG). The primary endpoint was infarct size as assessed by cardiac MRI. The abciximab group showed lower cTFC (median 14.1 [IQR 9.4-17.1]) than the tenecteplase group (18.2 [10.0-28.2]) (p=0.02), and the proportion of patients with TMPG grade 2/3 was higher in the abciximab group (90.3% vs. 67.7%; p=0.03). Major cardiac and cerebrovascular event rates did not differ; however, notably, 2/38 patients in the tenecteplase group experienced subacute stent thrombosis. At four months, there were no significant differences in infarct size between the tenecteplase and abciximab groups (17.0 g [9.6-27.5] vs. 21.1 g [11.3-35.0], p=0.33). CONCLUSIONS: Intracoronary administration of tenecteplase did not reduce infarct size compared to abciximab in STEMI patients undergoing PPCI. Tenecteplase exhibited poorer myocardial reperfusion and might be associated with increased subacute stent thrombosis.
No takes yet. Share an insight, caveat, or question.
Morales et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: